Plasma concentration monitoring of osimertinib and its active metabolites to assess clinical efficacy of osimertinib

Plasma concentration monitoring of osimertinib and its active metabolites to assess clinical efficacy of osimertinib - Plasma concentration monitoring of osimertinib and its active metabolites to assess clinical efficacy of osimertinib

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043773

Enrollment

Registered

2021-03-29

Start date

2018-01-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Taking osimertinib for EGFR mutation-positive inoperable or recurrent non-small cell lung cancer.

Exclusion criteria

Exclusion criteria: Clinical difficulties in this trial

Design outcomes

Primary

Measure	Time frame
To verify the efficacy of osimertinib, plasma concentration of osimertinib and its active metabolites (AZ5104, AZ7550) will be measured.	—

Secondary

Measure	Time frame
Patient background	—

Countries

Japan

Contacts

Public ContactTakae Okuno

Shimane University Hospital Medical Oncology and Respiratory Medicine

takae007@med.shimane-u.ac.jp0853-20-2580

Outcome results